Anders Lindholm | Vice President and Head of Drug Safety Therapeutic Area Inflammation and Immunology
Celgene

Anders Lindholm, Vice President and Head of Drug Safety Therapeutic Area Inflammation and Immunology, Celgene

Anders received his medical degree and certification at the Karolinska Institute in Stockholm, from which he also earned a PhD in Clinical Pharmacology and Transplantation Surgery.  He practiced as a transplantation surgeon in Sweden and was appointed Associate Professor in Transplantation Biology, affiliated with the Karolinska Institute. His scientific production includes more than 80 publications in peer reviewed journals. Subsequent to the academic career, Anders spent six years at Novo Nordisk as a Clinical Leader responsible for successful filings for a rapid acting insulin analogue. For the last 15 years Anders has been TA Safety Head at Johnson & Johnson, Shire and Celgene providing oversight for a department of physicians and scientists developing safety evaluations, benefit-risk assessments, and RMPs. Anders is currently engaged in how to further develop Benefit Risk tools within Celgene.

Appearances:



Drug Safety World Day 2 @ 15:20

Structured BR assessments: Industry perspectives on an evolving field

  • The DOING, and the CHALLENGES of structured BR assessments
  • Benefit-Risk Management and impact in the enterprise/outside the enterprise
  • The future of BR assessments

back to speakers